☆ 4.2 Editorial Material

Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)

Journal

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Volume 28, Issue 4, Pages 439-442

Publisher

WILEY

DOI: 10.1002/pds.4697

Keywords

-

Categories

Public, Environmental & Occupational Health Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Pharmacology & Pharmacy

Regulatory and HTA Considerations for Development of Real-World Data Derived External Controls

Lesley H. Curtis, Oriol Sola-Morales, Julien Heidt, Patrick Saunders-Hastings, Laura Walsh, Deborah Casso, Susan Oliveria, Tiffany Mercado, Robbert Zusterzeel, Rachel E. Sobel, Jessica J. Jalbert, Vera Mastey, James Harnett, Ruben G. W. Quek

Summary: Regulators and HTA bodies are familiar with using external controls derived from RWD to generate RWE. This paper emphasizes the need for more guidance and alignment among regulatory agencies and HTA bodies in terms of operational and methodological aspects. Practical guidelines for the responsible generation of fit-for-purpose RWE are discussed, including early engagement with regulators, consideration of appropriate and comparable external controls, ensuring adequate sample sizes, addressing data quality issues, selecting meaningful endpoints, and conducting sensitivity analyses.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Mathematical & Computational Biology

Some Biostatistical Considerations About Real-World Data and Evidence in Clinical Studies, Especially for Regulatory Purposes

Gregory Campbell

Summary: This article surveys the opportunities for using real-world data and evidence in clinical design and analysis to inform regulatory decision making. It discusses the bias for RWD, explores the possibilities of patient registries, and highlights the leadership by the FDA in real-world evidence.

STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2023)

Add to Collection

Article Genetics & Heredity

Real-world evidence in achondroplasia: considerations for a standardized data set

Yasemin Alanay, Klaus Mohnike, Ola Nilsson, Ines Alves, Moeenaldeen AlSayed, Natasha M. Appelman-Dijkstra, Genevieve Baujat, Tawfeg Ben-Omran, Sandra Breyer, Valerie Cormier-Daire, Pernille Axel Gregersen, Encarna Guillen-Navarro, Wolfgang Hoegler, Mohamad Maghnie, Swati Mukherjee, Shelda Cohen, Jeanne Pimenta, Angelo Selicorni, J. Oliver Semler, Sabine Sigaudy, Dmitry Popkov, Ian Sabir, Susana Noval, Marco Sessa, Melita Irving

Summary: Establishing a prospective, standardized registry for collecting real-world evidence on achondroplasia is important for improving understanding of the natural history, quality of life, and outcomes of this rare condition. Data elements include auxological measures, sleep studies, quality of life, and neurological manifestations. The registry will provide valuable information for clinical decision-making and management.

ORPHANET JOURNAL OF RARE DISEASES (2023)

Add to Collection

Editorial Material Multidisciplinary Sciences

Convention gives way to real-world relevance

Leigh Dayton

Summary: Less-established universities need to establish strong links with the industry in order to understand market demands and produce products that meet those demands.

NATURE (2021)

Add to Collection

Article Oncology

An overview of real-world data sources for oncology and considerations for research

Lynne T. Penberthy, Donna R. Rivera, Jennifer L. Lund, Melissa A. Bruno, Anne-Marie Meyer

Summary: Generating evidence on the use, effectiveness, and safety of new cancer therapies is crucial, and utilizing real-world data (RWD) is integral to understanding outcomes among patients. Careful consideration of different types of RWD sources is necessary to inform data source selection appropriate to the study question.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Medicine, General & Internal

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan

Hideki Maeda, Daniel Bin Ng

Summary: There is a growing trend in clinical development to use real-world data (RWD) to improve the efficiency of drug/medical device development. In regulatory approval, the use of RWD to generate real-world evidence (RWE) is currently undergoing active discussion. In this paper, the history and current situation of RWE are summarized, with a focus on its utilization for regulatory approval. The challenges and perspectives for registry research in Japan are also discussed.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Environmental Studies

Variation of truck emission by trip purposes: Cases by real-world trajectory data

Zhu Yao, Mi Gan, Qiujun Qian, Yu Qiao, Lifei Wei

Summary: This study analyzes massive trajectory data to decompose the relationship between truck trips and emissions from a trip chain perspective. It introduces a method to calculate on-road truck emissions considering different trip purposes and load state changes. The results show significant variations in real-world emissions from heavy-duty diesel trucks by trip purpose, with the highest variations in NOX and PM2.5 emission factors exceeding 21.06% and 14.24%, respectively. Comparison with previous studies demonstrates the accuracy and reliability of the proposed method in estimating truck emissions when accounting for different trip purposes.

TRANSPORTATION RESEARCH PART D-TRANSPORT AND ENVIRONMENT (2023)

Add to Collection

Article Pharmacology & Pharmacy

Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness

Nirosha Mahendraratnam, Kerra Mercon, Mira Gill, Laura Benzing, Mark B. McClellan

Summary: Research has shown that RWE has been used to support the regulatory effectiveness of oncology and rare disease treatments, but there is potential for expanding its use to other therapeutic areas for a more patient-centered approach.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Computer Science, Interdisciplinary Applications

Assessing real-world medication data completeness

Laura Evans, Jack W. London, Matvey B. Palchuk

Summary: Analyzing the completeness of certain diagnosis-medication couplets can serve as a proxy for assessing the overall completeness of medication data for an organization. Five reliable proxies were identified, with at least 87% observed completeness for specific diagnoses and medications.

JOURNAL OF BIOMEDICAL INFORMATICS (2021)

Add to Collection

Article Infectious Diseases

Characterizing patients with rare mucormycosis infections using real-world data

Yayue Zhang, Anita H. Sung, Emily Rubinstein, Michael Benigno, Richard Chambers, Nataly Patino, Jalal A. Aram

Summary: This study used the Optum electronic health record dataset to descriptively assess patients with invasive mucormycosis (IM). The results showed that IM occurred mainly in patients between 40 and 64 years old, Caucasian, and living in the Midwest. The most common comorbidity was essential primary hypertension. Only 33.72% of patients received antifungal treatment, with fluconazole and posaconazole being the most commonly used.

BMC INFECTIOUS DISEASES (2022)

Add to Collection

Article Pharmacology & Pharmacy

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data

Ha Young Jang, In-Wha Kim, Jung Mi Oh

Summary: This study found that a real-world evidence (RWE) study in Korea, which emulated the design of a randomized clinical trial (RCT), had consistent results with the RCT. It suggests that RWE has the potential to provide evidence for regulatory decision-making in countries where RCTs are difficult to perform.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Invited Commentary: Theoretical Considerations and Real-World Challenges for Research on Proxy Exposures and Ovarian Reserve

Brian W. Whitcomb

Summary: The study assessed the potential impact of urinary cadmium level on ovarian reserve using different modeling methods, which indicated that cadmium may affect ovarian aging. The recommendation is to carefully consider the modeling approach in studies related to ovarian reserve.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2021)

Add to Collection

Editorial Material Oncology

Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data

Gregory S. Calip, Niquelle Brown Wade, Jenny S. Guadamuz, Xiaoliang Wang, Rebecca A. Miksad, Kristen D. Whitaker

Summary: As awareness grows regarding the prevalence of cardiovascular comorbidity and mortality among breast cancer survivors, it is crucial to address race- and age-based disparities in cardiovascular-related deaths through clinical attention. Leveraging real-world data sources for cancer and cardiovascular disease prevention is essential for achieving cancer health equity and learning from all patients' experiences.

CANCER (2022)

Add to Collection

Review Medicine, General & Internal

Real-world evidence for regulatory decision-making: updated guidance from around the world

Leah Burns, Nadege Le Roux, Robert Kalesnik-Orszulak, Jennifer Christian, Jennifer Dudinak, Frank Rockhold, Sean Khozin, John O'Donnell

Summary: The importance of leveraging real-world evidence (RWE) for informed regulatory decisions in healthcare is gaining momentum. This article provides an assessment of the global regulatory landscape and regional availability of RWE frameworks and guidance. It also discusses potential opportunities and gaps for future development and harmonization in this field.

FRONTIERS IN MEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions

Shirley Wang, Sushama Kattinakere Sreedhara, Sebastian Schneeweiss

Summary: Studies that analyze digital data collected in clinical practice provide important insights for healthcare decision-makers. In this study, the reproducibility of 150 peer-reviewed studies was tested, showing strong reproducibility. Future original studies could improve reproducibility by providing more complete reporting.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Public, Environmental & Occupational Health

Trial designs using real-world data: The changing landscape of the regulatory approval process

Elodie Baumfeld Andre, Robert Reynolds, Patrick Caubel, Laurent Azoulay, Nancy A. Dreyer

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)

Add to Collection

Editorial Material Medical Informatics

When Context Is Hard to Come By: External Comparators and How to Use Them

Christina Mack, Jennifer Christian, Emma Brinkley, Edward J. Warren, Marni Hall, Nancy Dreyer

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2020)

Add to Collection

Article Medical Informatics

Masking in Pragmatic Trials: Who, What, and When to Blind

Jennifer B. Christian, Emily S. Brouwer, Cynthia J. Girman, Dimitri Bennett, Kourtney J. Davis, Nancy A. Dreyer

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2020)

Add to Collection

Article Medical Informatics

Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims

Cynthia J. Girman, Mary E. Ritchey, Ann Marie McNeill, Karolina Andersson Sundell, Robert J. Meyer

Summary: The FDA will issue guidance on using real-world evidence to support new indications or expanded product labeling, drawing parallels from previous shifts in paradigm such as with patient reported outcomes.

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19

Nancy Dreyer, Natalia Petruski-Ivleva, Lisa Albert, Damir Mohamed, Emma Brinkley, Matthew Reynolds, Stephen Toovey

Summary: Individuals with underlying autoimmune conditions who use medications for these conditions are more likely to experience persistent COVID-19 symptoms, including shortness of breath and fatigue, after 30 days compared to those not using such medications. This suggests that early intervention may be necessary for this vulnerable population.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study

J. Bradley Layton, Joan Forns, Mary Ellen Turner, Colleen Dempsey, Jennifer L. Bartsch, Mary S. Anthony, Heather E. Danysh, Mary E. Ritchey, George Demos

Summary: Long-term study on patients with Parkinson's disease-related psychosis showed that the risk of falls/fractures associated with pimavanserin did not increase compared to other antipsychotic medications, and even suggested a decreased risk.

DRUGS-REAL WORLD OUTCOMES (2022)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products

Cynthia J. Girman, Mary E. Ritchey, Vincent Lo Re

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Alternative analytic and matching approaches for the prevalent new-user design: A simulation study

Michael Webster-Clark, Panagiotis Mavros, Elizabeth M. Garry, Til Sturmer, Shahar Shmuel, Jessica Young, Cynthia Girman

Summary: Multiple analytic methods can estimate treatment effects without bias in a prevalent new user cohort. However, researchers should be cautious of introducing bias when selecting controls for complex matching strategies beyond the initially proposed time-conditional propensity score (TCPS).

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

Add to Collection

Article Health Care Sciences & Services

Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design

Matthew W. Reynolds, Alex Secora, Alice Joules, Lisa Albert, Emma Brinkley, Tom Kwon, Christina Mack, Stephen Toovey, Nancy A. Dreyer

Summary: This study assessed the real-world effectiveness of three COVID-19 vaccines and found all three to be highly effective.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2022)

Add to Collection

Article Infectious Diseases

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Matthew W. Reynolds, Yiqiong Xie, Kendall B. Knuth, Christina D. Mack, Emma Brinkley, Stephen Toovey, Nancy A. Dreyer

Summary: This study used adult community volunteers to obtain systematic information on vaccine effectiveness and breakthrough infections, showing a lower breakthrough infection rate in fully vaccinated individuals, with most cases being asymptomatic or having mild symptoms compared to unvaccinated cases.

INFECTION AND DRUG RESISTANCE (2022)

Add to Collection

Article Clinical Neurology

Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis

Colin Anderson-Smits, Mary E. E. Ritchey, Zhongwen Huang, Shailesh Chavan, Nizar Souayah, Hakan Ay, J. Bradley Layton

Summary: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare disease where the immune system attacks the nerves. Intravenous immunoglobulin (IVIG) is recommended as one of the first-line treatments for CIDP. This study aimed to gather information on the day-to-day use of IVIG by patients with CIDP.

NEUROLOGY AND THERAPY (2023)

Add to Collection

Article Clinical Neurology

Intravenous Immunoglobulin Initiation in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims-based Cohort Study

J. Bradley Layton, Mary E. Ritchey, Zhongwen Huang, Shailesh Chavan, Hakan Ay, Nizar Souayah, Colin Anderson-Smits

Summary: The study examined the characteristics of patients with CIDP who received IVIG treatment in the USA. The results showed that patients often had additional diagnoses of other diseases, such as neuropathy, hypertension, and diabetes, before starting IVIG. They also frequently experienced CIDP features and symptoms that affected their daily lives. Diagnostic procedures related to CIDP were common in the months leading up to IVIG initiation. The study also found that patient characteristics were generally similar regardless of the specific IVIG product used.

NEUROLOGY AND THERAPY (2023)

Add to Collection

Article Medicine, General & Internal

Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice

Nancy A. Dreyer, Christina Mack

Summary: Real-world evidence (RWE) is derived from real-world data (RWD) generated by clinicians and patients in everyday care settings. RWE is used to evaluate the real-world performance of medical interventions, services, and diagnostics, with a focus on diverse patient groups that may not be typically studied in traditional randomized clinical trials (RCT). This article provides guidance on study design and execution for clinicians interested in using RWE, including considerations about study participant representativeness, data transparency, and potential sources of bias. The authors also highlight the growing role of RWE in clinical, regulatory, and payer decision-making.

PRAGMATIC AND OBSERVATIONAL RESEARCH (2023)

Add to Collection

Article Clinical Neurology

No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines study

Rishi J. Desai, Mufaddal Mahesri, Su Been Lee, Vijay R. Varma, Tina Loeffler, Irene Schilcher, Tobias Gerhard, Jodi B. Segal, Mary E. Ritchey, Daniel B. Horton, Seoyoung C. Kim, Sebastian Schneeweiss, Madhav Thambisetty

Summary: A study evaluated the potential association between phosphodiesterase-5 inhibitors and reduced incidence of Alzheimer's disease and related dementia. The results from Medicare claims and cell culture-based assays showed no evidence supporting this hypothesis.

BRAIN COMMUNICATIONS (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.